GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » EV-to-EBITDA

Centogene NV (Centogene NV) EV-to-EBITDA : -4.14 (As of May. 04, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Centogene NV EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Centogene NV's enterprise value is $61.13 Mil. Centogene NV's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-14.76 Mil. Therefore, Centogene NV's EV-to-EBITDA for today is -4.14.

The historical rank and industry rank for Centogene NV's EV-to-EBITDA or its related term are showing as below:

CNTG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.92   Med: -1.9   Max: -0.57
Current: -4.14

During the past 7 years, the highest EV-to-EBITDA of Centogene NV was -0.57. The lowest was -29.92. And the median was -1.90.

CNTG's EV-to-EBITDA is ranked worse than
100% of 116 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.29 vs CNTG: -4.14

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Centogene NV's stock price is $0.44285. Centogene NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.710. Therefore, Centogene NV's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Centogene NV EV-to-EBITDA Historical Data

The historical data trend for Centogene NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV EV-to-EBITDA Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial - -13.97 -4.05 -3.10 -2.12

Centogene NV Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.10 -2.19 -1.45 -2.12 -

Competitive Comparison of Centogene NV's EV-to-EBITDA

For the Diagnostics & Research subindustry, Centogene NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centogene NV's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Centogene NV's EV-to-EBITDA falls into.



Centogene NV EV-to-EBITDA Calculation

Centogene NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=61.128/-14.762
=-4.14

Centogene NV's current Enterprise Value is $61.13 Mil.
Centogene NV's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centogene NV  (NAS:CNTG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Centogene NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.44285/-0.710
=At Loss

Centogene NV's share price for today is $0.44285.
Centogene NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.710.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Centogene NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Centogene NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Centogene NV (Centogene NV) Business Description

Traded in Other Exchanges
Address
Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.